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Manufacturing of more-than-minimally manipulated autologous cell therapies presents a number of unique challenges
driven by complex supply logistics and the need to scale out production to multiple manufacturing sites or near the patient
within hospital settings. The existing regulatory structure in Europe and the United States imposes a requirement to establish
and maintain comparability between sites. Under a single market authorization, this is likely to become an unsurmountable
burden beyond two or three sites. Unless alternative manufacturing approaches can be found to bridge the regulatory
challenge of comparability, realizing a sustainable and investable business model for affordable autologous cell therapy
supply is likely to be extremely demanding. Without a proactive approach by the regulators to close this “translational gap,”
these products may not progress down the development pipeline, threatening patient accessibility to an increasing number of
clinician-led autologous cellular therapies that are already demonstrating patient beneﬁts. We propose three prospective
manufacturing models for the scale out/roll out of more-than-minimally manipulated clinically led autologous cell therapy
products and test their prospects for addressing the challenge of product comparability with a selected expert reference panel
of US and UK thought leaders. This paper presents the perspectives and insights of the panel and identiﬁes where opera-
tional, technological and scientiﬁc improvements should be prioritized. The main purpose of this report is to solicit feedback
and seek input from key stakeholders active in the ﬁeld of autologous cell therapy in establishing a consensus-based
manufacturing approach that may permit the roll out of clinically led autologous cell therapies.
Key Words: autologous cell therapy, comparability, GMP, manufacturing, point-of-care, scale-outIntroduction
Recent analysis by Foley and Whitaker (1) has shown
that an increasing number of clinician-led (i.e.,
clinical trials sponsored by an institution), predomi-
nantly autologous cellular therapies are demon-
strating beneﬁts to patients. Often involving complex
routes of clinical intervention, these clinician-led
therapies span those in which a degree of clinical
adoption and proven efﬁcacy already exists to those
in which trials will be carried out under regulatory
constraints more familiar with the regulatory route
that industry-led cellular therapies must traverse (1).
Most companies seeking highly proﬁtable business
models work predominantly with scalable allogeneic
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market (1). Smaller-scale autologous therapies must
follow alternative manufacturing and distribution
approaches, dependent on the product (disease indi-
cation and prevalence), the method of preservation of
the product and the ﬁt with the systems in place at the
ﬁnal destination in the clinic (2). This may involve, for
example, a central processing facility serving a number
of clinical sites or a distributed model that requires
localized processing within a hospital unit or
manufacturing in-theatre or at the bedside through
the use of closed or functionally closed automated
processing systems.
The regulatory approach taken for speciﬁc
autologous cell therapies is dictated by their intendedentre for Innovative Manufacturing in Regenerative Medicine, Centre for
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facture. In some therapeutic cases, particularly in the
orthopedic and cosmetic sectors, harvested cells are
minimally manipulated (eg, by aseptic enrichment or
separation techniques) and returned to the same
patient. In most others, there is a requirement to
expand the number of harvested cells in in vitro
culture to generate a sufﬁcient dose for therapeutic
use. This expansion in culture, being considered by
regulators to be more than minimal (or substantial)
manipulation, raises considerable hurdles and chal-
lenges for both developers and regulators (3e6).
Manufacturing of more-than-minimally manipu-
lated (MTMM) autologous cell-based therapies
presents a number of speciﬁc challenges driven by
complex supply logistics and the need to scale out
(increasing the number of batches) production to
multiple manufacturing sites or near to the patient
within hospital settings. The existing regulatory
structure in Europe and the United States sensibly
imposes a requirement to establish and maintain
comparability (demonstration of product equiva-
lence) between sites.
At best, the assurance of comparability is ach-
ieved through a combination of in vitro studies,
analytical testing and biological assays. Recently
however, a consortium of stakeholders taking part
in the Technology Strategy Board-funded Value
Systems and Business Models project, known as
“VALUE” (7,8), suggested that extensive safety
testing of ﬁnal cell product, while practical in
the allogeneic setting, may not be feasible in the
MTMM autologous setting. They concluded that
because of restrictions related to small lot sizes,
short shelf lives and the clinically limited time avail-
able for product and lot release testing it may
not be possible to demonstrate comparability for
additional manufacturing sites without costly and
time-consuming conﬁrmatory clinical qualiﬁcation
studies.
The cell therapy industry has experienced
continued wrangling between regulators, lawmakers
and practitioners and uncertainty as to the data
required to establish quality, safety and efﬁcacy of
cell therapies (9e14), particularly with the Interna-
tional Society for Cell Therapy (ISCT) position on
potency assays receiving recent attention (15).
Against this backdrop, with point-of-care manu-
facturing not envisaged under current US and EU
regulatory frameworks, with few MTMM autologous
cell therapies on the market, for example, MACI
(Genzyme), Provenge (Dendreon), ChondroCelect
(Tigenix) and LaViv (Fibrocell Science), and with no
precedent for a multi-site MTMM autologous cell
therapy in Europe, it is clear that alternative cost-
effective manufacturing approaches are required topermit the roll out of clinically led autologous cell
therapies.
We propose three prospective manufacturing
models for the scale out/roll out of MTMM, clini-
cally led autologous cell therapy products, consider
how they may be enabled and test their prospects for
addressing the challenge of product comparability
under the principles of the existing regulatory land-
scape. This paper presents the perspectives and in-
sights of a small, selected expert reference panel of
US and UK thought leaders from the industrial and
regulatory community. It highlights the issues raised,
identiﬁes alternative manufacturing approaches,
identiﬁes where operational, technological and sci-
entiﬁc improvements should be prioritized and
where new enabling science is still required.The regulatory challenge
Under the existing US and EU regulatory frame-
works, cellular products that have been subject to
more-than-minimal manipulation and/or do not
carry out the same function in the recipient as the
donor (non-homologous use) are broadly classiﬁed
as either medicinal products (EU) or biologics (US),
with relatively few regulatory distinctions made be-
tween autologous and allogeneic therapies and the
characteristics that differentiate them (16,17).
In the autologous setting, the logistical hurdles
associated with the clinically limited time available to
transport harvested donor patient cells to the
manufacturing or processing site and their return back
to the clinical site for administration dictates both the
manufacturing model (centralized versus distributed)
and the clinical-site model (direct delivery versus
clinical-site manipulation). This presents a number of
ways of realizing the manufacturing/clinical supply
process in multiple, distributed locations (Figure 1).
The requirements for regulatory approval, Good
Manufacturing Practice (GMP) and the level of vali-
dation relate, in part, to which sites are used for each
element of the manufacturing and clinical process.
Manufacturers of autologous cell therapy prod-
ucts often introduce changes to manufacturing pro-
cesses both during development and after market
approval. Under the existing regulatory structure in
Europe and the United States, when changes are
made to a manufacturing process, the manufacturer
is required to demonstrate comparability, that is, a
demonstration of product equivalence before and
after the change. This includes situations in which a
second or reconﬁgured production line/unit, facility,
location or supplier is brought on stream or when
multiple sites of manufacture are introduced.
The scale out/transfer of manufacturing processes
to multiple sites established before pivotal Phase III
Figure 1. Alternative routes for manufacturing and clinical site process transfer and product delivery. The requirements for regulatory
approval, GMP and the level of validation relate, in part, to which sites are used for each element of the manufacturing and clinical process,
which in turn dictates how the manufacturing model may be implemented.
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Under a single market authorization, however, the
roll out of locked-down processes to more than two
or three sites (Nþ1 model) is likely to become an
unsurmountable challenge, even within the same
regulatory jurisdiction (7,18) (Figure 1). The chal-
lenge that this poses is no better illustrated than
by Dendreon’s conspicuous and costly issues with
their multiple manufacturing site model and uptake
of their autologous prostate cancer product
(Provenge) (19).1The following model convention is used to differentiate the origin and scale
of the potential routes for manufacturing roll out to multiple sites: Transfer
of a product/process from an academic or hospital laboratory to a regulated
manufacturing site (0þ1 model); transfer to one or more additional
manufacturing/production line(s) or to a regulated manufacturing loca-
tion(s) within the same jurisdiction, either before (N model) or after Phase
III clinical trials (Nþ1 model); transfer of product/process to regulated
manufacturing site(s) within different jurisdictions (NþMmodel), that is, a
site in each of the major geographical markets, transfer to 20 or 30 pro-
cessing sites (eg, sites in international Centers of Excellence for major
clinical specialisms) or transfer to 100 to 500 processing machine platforms,
that is, systems “within a GMP setting” or “GMP in-a-box” systems
(an example of true process scalability).The scientiﬁc challenge
Approaches to establishing the comparability of cell
therapy products through manufacturing process
changes are predicated on manufacturing reproduc-
ibility such that products are produced with consistent
quality attribute proﬁles. The core of the scientiﬁc
problem is to determine both the allowable variation
in the product necessary to deliver quality, safety and
efﬁcacy and the achievable variation in the
manufacturing process, taking account of variation of
input or starting materials and variation in the patient
population within the autologous setting. The chal-
lenge is doing this with the additional variation asso-
ciated with multiple manufacturing sites while
containing cost of goods and costs of validation.
Persistent issues underpinning the challenge are asso-
ciated with a poor understanding of the mechanism of
action (MOA), poor deﬁnition of product character-
istics that inﬂuence its quality, safety and efﬁcacy and
poor understanding of how changes or variation in the
manufacturing process affect these characteristics.
Unless alternative manufacturing approaches can
be found to bridge the regulatory and scientiﬁc
1036 P. Hourd et al.challenges of comparability, realizing a sustainable
and investable business model for affordable autol-
ogous cell therapy supply is likely to be extremely
demanding, even within a clinical setting. Without a
proactive approach by the regulators to close this
“translational gap,” these products may not progress
down the development pipeline. This threatens
patient accessibility to an increasing number of
clinician-led autologous cellular therapies that are
already demonstrating beneﬁts to patients (1).Methods
The three manufacturing models proposed are pre-
mised on their ability to reduce the risk proﬁle of the
product and the manufacturing process. The models
are speciﬁcally applied to the manufacture of
MTMM autologous cells (deﬁned as donor cells that
are derived from the patient who is the sole recipient
of the cell product, intended for use for the same
[homologous] or different [non-homologous] essen-
tial function) and do not consider application to cells
that are genetically modiﬁed or associated with a
device.
Framed by the question, “How can developers
provide transferable methods with sufﬁcient evidence
of comparability across multiple manufacturing sites
without the need for extensive clinical qualiﬁcation
studies?” a selected expert reference panel of US and
UK thought leaders was assembled to review and
assess each of the manufacturing models. The panel
comprised three prominent industrialists active
within the Regenerative Medicine or Advanced
Therapy ﬁeld, a regulatory consultant and a regula-
tory GMP inspector with international reach. Par-
ticipants were invited to respond individually by
means of a semi-structured interview process to six
open questions: (i) Do you think this model could
have a positive impact on the development of
MTMM autologous therapies? (ii) Can you explain
what major challenges/barriers such a model may
face? (iii) Are there any regulatory requirements that
are speciﬁc to either the European Union or the
United States that could make the implementation of
this model more challenging? (iv) How do you think
this model may affect the whole development process
for an MTMM autologous cell therapy product? (v)
Do you think that this model could be modiﬁed to
make it more feasible from a regulatory perspective,
or is there an alternative model? (vi) What tractable
science/technologies are available or required to
enable this model?
For each of the manufacturing models and each
of the questions posed, the panelists’ responses were
segmented into a series of discrete statements.
Statements were then coded and assigned toemerging categories, which were then reﬁned into a
series of pivotal questions. Validation of the catego-
rization process involved a review of the features of
each category to ensure distinctiveness and to ensure
that the ascribed questions reﬂected the statements
that they subsumed. The outcome of this analysis
was used to format and map the following discussion
to each of the proposed models. Alternative
manufacturing models emerging from the panelists’
responses were also captured to solicit further
assessment and comment.Results
Manufacturing model 1: limited cell expansion
The model asserts that autologous cellular products
manufactured by use of a minimal number of popu-
lation doublings during culturing may reduce the
extent of the characterization/validation studies
needed to show comparability between manufacturing
sites under a single product licence. The premise of
the model is that limiting the number of ex vivo
population doublings (eg, one or two) required to
generate the therapeutic product (with or without an
allowance for pooling) minimizes the risk factors
associated with the manufacturing process and the
product by (i) reducing the complexity of the
manufacturing process, for example, fewer media
changes/formulations, fewer raw materials, fewer
manual manipulations and so forth and improving
reproducibility, and (ii) reducing the risk of changes to
the biological characteristics, physiological function(s)
or structural properties of the cells associated with
expansion of the cells before their return to the
patient.Can you ensure consistent cell function by deﬁning a
stable and predictable cell composition and the limits for
acceptable changes?
The case for the limited expansion model was
supported, with experts agreeing that minimizing
the number of cell divisions required to generate
efﬁcacious autologous cell product for the majority
of indications is inherently safer from the point of
view of in vitro cell stability and potential for bio-
divergence.
However, from the regulator’s perspective, cell
manipulation may not necessarily lead to apparent
changes in cell behaviour of the gross phenotype of
the cells after in vitro culture. Even minimal expan-
sion in culture is therefore judged to have the
potential to alter cells in a way that is difﬁcult to
predict without subsequent testing of the biological
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the cells (4,20e22).
The perspective shared by the experts was that a
limited expansion model would be predicated on the
cell seeding and expansion approach and on
demonstrating that the risk of biological divergence
or drift over time is more tied to the number of
population doublings than it is to how the ﬁrst
doubling is carried out (accepting the maintenance of
sterility and effective depletion of contaminating
cells), that is, the more-than-minimal manipulation
paradigm. Experts referred to the importance of
establishing a scientiﬁc basis for the limits of safe
expansion. This would enable controls to be set for
the permissible number of passages and population
doublings to minimize the potential for change [akin
to the viral seed lot system used in vaccine produc-
tion (23)] and for deﬁning the edge of failure, that is,
the point at which cells in culture begin to drift or
acquire genetic and epigenetic changes. In empha-
sizing the need to establish these limits early in
the development stage, current test systems were
seen by some experts as lacking the sensitivity and
speciﬁcity to adequately detect some of these cell
transformations.
It will be important to understand the nature and
extent of the changes to the manufacturing process
and how they will affect the safety proﬁle of the ﬁnal
product. In this context, some experts expressed the
view that a stable cell line or a cell line that changes in
a predictable manner should facilitate assessment of
the impact of these changes, providing there is suf-
ﬁcient knowledge of the relevant quality attributes of
the ﬁnal product. Challenge studies that use non-
or under-functioning lots (ie, purposely degraded or
over-expanded) early in clinical development
pathway are a key component (24). These would
enable the criteria that provide limits for acceptable
changes to be deﬁned, for example, that distinguish
cellular changes that are irrelevant to a product’s
clinical function from potentially unsafe alterations.Can you ensure manufacturing and lot-to-lot consistency
in light of donor-derived starting material variability?
The operational advantages of the less complex
manufacturing processes associated with the limited
expansion model were underlined, exempliﬁed by a
reduction in the prominent and cumulative risk fac-
tors associated with multiple, often manual, manip-
ulation steps (eg, operator error/training, tracking/
mix-ups, contamination and cross-contamination).
However, despite the potential reduction in safety
concerns and in operator induced variation, experts
shared the view that variability associated with
donor-derived starting material (ie, input variation)would still be the critical factor inﬂuencing the
prospects for reproducible manufacturing.
The impact of both intra- and inter-individual
variation on the quality of the starting material was
stressed, in particular differences arising from the cell
isolation procedure and associated sensitivities to
operator technique, the tissue/organ biopsy site and
the sample characteristics imposed by the disease
state or other characteristics of the individual.
Experts referred to the need for a greater
emphasis on identifying critical donor characteristics
(eg, sex, age, weight, state of health, etc) and test
criteria for donor material selection. This would
permit minimum thresholds for justifying the process
input to be established and patient speciﬁc end
points relative to the characteristics of the of the
patient to be derived. Linked to end-stage potency
evaluation, an improved understanding of the phar-
macokinetic/pharmacodynamic proﬁle of the cell
product was stressed as having a key role in relating
cell function in vitro to preclinical beneﬁt and
appropriate dose and dose regimen design. Overall, a
better understanding of the input variables that in-
ﬂuence ex vivo expansion potential/efﬁciency and
that affect process reproducibility and product out-
comes in terms of the functional potential and
kinetics of cells, it was suggested, would allow the
quality control of the source and nature of starting
materials. This would enable the determination of
rational operating limits within which a predictable
outcome can be assured in the process and for the
product.Can you deﬁne and characterize the safety factors/quality
attributes of ﬁnal product sufﬁcient to ensure consistent
cell function with limited material and time available for
testing?
Cell product characterization—speciﬁcally identity,
purity, potency and safety—underpins regulatory
expectations for the assessment of process and
product stability, reproducibility and comparability
after a process change or across manufacturing sites.
The regulatory expectations for the degree of assur-
ance and stringency of the data required to demon-
strate comparability will depend on the nature and
extent of the change and the stage of product
development. Some experts raised the question as to
how the regulator decides what is sufﬁcient, reﬂect-
ing the current vigorous debate in this area (9e14).
The extent and depth of the testing program is
determined by the potential impact of the changes on
the physicochemical and biological properties of the
product and in practice, the availability of suitable
analytical techniques correlating critical quality at-
tributes with the MOA or clinical efﬁcacy and safety
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that bridges these changes could encompass exten-
sive in vitro characterization, with or without non-
clinical or clinical testing (or both) (25). From the
regulator’s perspective, with both US an EU regu-
latory bodies subscribing to ICH Q5E (25), the
expectation is that comparability testing programs
consider an assessment of the impact of changes to
the product quality attribute proﬁle caused by the
manufacturing process change as it relates to the
safety and efﬁcacy of the product. A recent report by
the Potency Working Group (formed by the ISCT
Process and Product Development Committee) has
asserted that without the inclusion of measures of
biological activity in the testing program (including
surrogate measures of potency that allow prediction
of activity in vivo), product comparability cannot be
established after changes, even minor changes, are
made to the manufacturing process without non-
clinical or clinical testing (or both) (15). This would
represent the worst-case scenario from a developer’s
perspective, a viewpoint that was shared by some of
the experts.
The challenge, given the large variety of potential
autologous cell therapies under development, will
therefore be to identify potential biomarkers and
develop potency assays that have relevance to the
intended clinical use. If such measures could be
developed early enough in the product lifecycle, that
is, as the manufacturing platformmatures from Phase
I to commercial lockdown, the view was that these
tests could provide more discriminating data than in
vivo preclinical trials in contrived animal models. By
allowing prediction of activity in vivo beyond the
measures required for lot release, characterization
proﬁles could be used to differentiate critical and
non-critical characteristics, to demonstrate that
routine potency is achieved and ultimately, to rein-
force the demonstration of comparability.
Even if the MOA(s) of the cell product can be
elucidated, experts agreed that developing valid and
quantitative predictive surrogate tools applicable to
such extensive testing in the autologous setting,
particularly in the limited expansion setting, would
be challenging. This would require signiﬁcant ad-
vances in the development of new rapid, non-
destructive, inexpensive, highly precise and sensitive
characterization technologies and test methods to
overcome constraints related to small lot sizes, short
shelf lives and the clinically limited time available for
pre-clinical and lot release testing. Examining other
possibilities, experts questioned whether the pooling
of donor samples from an individual patient could
provide a solution to product lot volume limitations.
Concerns were raised relating to inter-site variability
(intra-patient) and ethical compliance surroundingthe use of multiple biopsy procedures for the supply
of validation material.
Complications arising from the lack of harmoni-
zation and standardization of assays and the
requirement for more predictive safety and func-
tional biomarkers for use in biologically relevant
animal models and for qualifying additional surro-
gate end points was emphasized. This reﬂects the
emphasis currently placed on standardization of po-
tency assays and cell characterization by organiza-
tions such as the ISCT and the Alliance for
Regenerative Medicine in the United States and the
British Standards Institution in the United
Kingdom. According to one panelist, this also un-
derlines the need for more sophisticated genetic,
epigenetic and proteomic analyses that might be
predictive of increased risk or (pre)clinical beneﬁt
and that might detect changes earlier than the cor-
responding clinical end point.Manufacturing model 2: incremental validation
(a risk-based approach)
The premise of the model is that MTMM autologous
cell therapies are manufactured at multiple sites,
released “proportional to the degree of risk” on the
basis of the product release speciﬁcations found in
the original license and incrementally validated after
marketing (continuous validation). The model as-
serts that a stratiﬁed risk-beneﬁtebased approach
supported by post-market surveillance would allow
incremental cost-effective scale out/roll out to addi-
tional manufacturing sites, reducing the extent of the
characterization/validation studies needed to show
comparability between manufacturing sites under a
single product licence.Can you ensure GMP uniformity across multiple
manufacturing sites?
The challenge of manufacturing consistency and
conformance to GMPs for small developing com-
panies and product developers in academic or hos-
pital settings, which in many cases are transitioning
from non-GMP facilities or facilities accredited as
tissue establishments, is well recognized (26). Ex-
perts agreed that replicating and qualifying additional
facilities to GMP standards is expected to be rela-
tively straightforward, notwithstanding the business
risks associated with the increase in capital (and
operational) expenditure and the time and cost
involved in regulatory compliance. Implementing
GMP facilities in parallel (ie, the N model)1 from the
outset, that is, under a single market authorization
application variation, could signiﬁcantly reduce the
time and cost for data submission, particularly if the
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utilizing the same team of regulatory inspectors.
However, despite these advantages, one expert was
emphatic that this approach would not be commer-
cially acceptable.
Often requiring new capabilities within an orga-
nization and its people, opportunities to minimize
differences between sites in key areas of risk and
ensure consistency and quality were highlighted. For
example, standardizing equipment, utilities, mate-
rials and supplies, implementing multi-site control
and management strategies to mitigate risks of add-
ing people to the process, provision of a centralized
(re)training at a reference site and implementing a
single overarching quality system and control plan
for manufacturing process oversight.
Experts also speciﬁed the importance of under-
standing the regulatory environment in different
geographies. This is essential to reduce uncertainty
in the data requirements for GMP compliance (eg,
manufacturers in the United States are exempt from
many of the GMP requirements during Phase I tri-
als) and to reduce the impact of differing healthcare
management, administration and legal control sys-
tems on GMP facilities and on clinical trial design
and authorization.Can you ensure a consistent MTMM autologous product
by deﬁning reliable product release speciﬁcations?
A well-deﬁned manufacturing process with its asso-
ciated process controls ensures that acceptable prod-
uct is produced on a consistent basis. However, with
limited manufacturing experience and under tradi-
tional process validation approaches (with the use of a
limited number of product consistency lots) and end
product quality control systems, manufacturing pro-
cesses are often poorly speciﬁed and locked in to
narrow speciﬁcation criteria at the time of approval.
In this context, experts referred to the impact of
input variability associated with donor-derived start-
ing material and the ethical concerns surrounding
the acquisition of the multiple product cell lots that
are required for such traditional process validation
studies (eg, are repeated procedures for draining
patient bone marrow for use in validation studies
ethically justiﬁable?).
From a regulatory perspective, it was perceived
that the tests and analytical procedures chosen to
deﬁne the product speciﬁcations under a traditional
end-product testingebased product release regime
generally would not be considered adequate to assess
the impact of manufacturing process changes or site
transfer. Typically, these speciﬁcations are chosen to
conﬁrm the routine quality of the product (eg, ste-
rility, identity) rather than to fully characterize it.A manufacturing process change is likely to require a
complete or limited repetition of the characterization
activity that was conducted for the market authori-
zation application (25). Despite the expectation that
the level of characterization required by the regulator
may be reduced with the addition of subsequent
manufacturing sites beyond a certain threshold (eg,
n > 6), experts agreed that this level of testing would
still present signiﬁcant practical challenges in the
autologous setting for the reasons already described.
The perspective of two panelists was that
completion of process validation studies should be
sufﬁcient for regulatory approval of additional
manufacturing sites, referring to analogous ap-
proaches for bone marrow transplantation and the
preparation and production of radiopharmaceuticals
in positron emission tomography centers. The chal-
lenge for autologous cell therapy manufacturers,
however, is in how to apply process validation to a
manufactured lot of patient cells when that same lot
is intended for treatment of the patient.
New concepts within the process validation
guidance (27,28), which put forward continuous
process veriﬁcation as a more progressive and graded
approach, afford manufacturers with new possibil-
ities. From a European perspective, panelists sug-
gested that complete validation of the registered
process and control strategy in the ﬁrst site might
permit a reduction in the characterization burden for
the validation of processes at subsequent GMP-
compliant manufacturing sites. The expectation,
however, was that critical phases of manufacture and
material control not addressed by application of the
ﬁnished product speciﬁcation alone would still
require additional testing.
Typically, the process validation study must be
completed successfully and a high degree of assur-
ance in the process must be achieved before com-
mercial distribution of a product. From a US
perspective, one panelist advocated a strategy anal-
ogous to the bone marrow transplantation approach,
which was developed with site accreditation, adher-
ence to standard operating procedures and classiﬁ-
cation or validation of sites through the practice of
the therapeutic approach. Under US Food and Drug
Administration (FDA) process validation guidance
(27), the process performance qualiﬁcation protocol
can be designed to release process performance
qualiﬁcation lots for patient treatment before com-
plete execution of the protocol steps and activities,
that is, concurrent release. The approval of subse-
quent manufacturing sites could be based on a con-
current release program in which samples from each
lot or a signiﬁcant proportion of lots can be evaluated
in a more extensive biosafety testing program in
non-clinical models. This would provide statistical
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means of the qualiﬁed process routinely exhibit
consistent potency while data are accrued in clinical
practice under a continued process veriﬁcation
phase.
These approaches call for an evaluation of safety
speciﬁcations that take into account the beneﬁts of
the cell therapy, corresponding levels of perceived
risks, the possible practical limitations and the
possibilities for risk mitigation and management.
Expectations were that these risk-based product
release approaches would be discouraged by many
regulatory bodies because of the potentially wide
variety of cell types and treatments, their inherent
biological variability and complications caused by
the underlying natural disease course or other
co-morbidities associated with many autologous
products.
However, with the European Medicines Agency
and FDA placing more emphasis on post-market
surveillance, some experts indicated that such
approaches may be appropriate for a number of
speciﬁc fast-track or orphan designation regulatory
pathways to expand access to treatments for unmet
medical conditions and ultra-rare or life-threatening
diseases. These include the fast-track, priority
review and accelerated approval programs in the
United States, which have recently been expanded
under the FDA Safety and Innovation Act 2012
(FDASIA) to allow sponsors to request that their
therapy be designated as a “breakthrough therapy”
(29).
One panelist pointed to regulatory trends in
Japan and South Korea that consider different eval-
uation approaches on the basis of adaptive licens-
ing or conditional marketing approvals. These
approaches are grounded on stepwise learning and
iterative phases of data accrual and regulatory
re-evaluation, which allows commercial sale in
certain instances while pivotal trials are underway.
In South Korea, for example, this has recently
led to the approval of an autologous bone marrowe
derived mesenchymal stromal cell (MSC) therapy
product (HeartiCellgram-AMI; PharmiCell Co Ltd)
and the world’s ﬁrst allogeneic, off-the-shelf
MSC-based product (Cartistem; Medipost Co Ltd).
According to Ancans (30), a similar regulatory de-
cision has seemingly been adopted for the Osiris
Therapeutics Inc allogeneic MSC product Prochy-
mal. In May 2012, the company was granted an
authorization for the treatment of acute graft-versus-
host disease in children under Health Canada’s
Notice of Compliance with conditions, which is an
authorization to market on the condition that the
manufacturer undertakes additional studies to verify
the clinical beneﬁt (30). It should be noted thatProchymal has since received approval by the New
Zealand Regulatory Agency (Medsafe) under their
priority review scheme; it is currently available in the
United States under an “Expanded Access Program”
(so-called “compassionate use”), has received an
Orphan Drug designation in the European Union
and will be evaluated in Switzerland under their
agency’s (Swissmedic) “Rapid Authorization Proce-
dure.” In Japan, too, there is emerging evidence that
induced pluripotent stem cell therapies may be given
an easier path to the clinic in the near future as the
government drives to capitalize on the technology. A
prospective revision in the drug law is expected to
fast-track therapies that appear to be effective in
Phase II or Phase III trials (31).Can you ensure MTMM autologous product consistency
by deﬁning a set of critical process parameters and
material attributes?
That the “product is the process” currentlymeans that
there are very signiﬁcant couplings between the design
of the product and the design of the process and pro-
duction system. A critical variable still to be estab-
lished for cell therapy products is the allowable
variation in the critical parameters required for prod-
uct performance, for example, the key components of
the product speciﬁcation deﬁning what must be ach-
ieved by manufacturing (18). However, the interpre-
tation and comparison of data used to support GMP
sterile manufacture compliance (eg, clean room clas-
siﬁcation, sterility testing), materials speciﬁcation,
clinical qualiﬁcation and product release (eg, pheno-
typic markers and potency assays) is hampered by a
lack of standardization in applicable test methods and
acceptance criteria. Experts referred to the importance
of developing uniform International Standards and
additional consensus guidelines for the development,
validation and standardization of capable quality
control (QC) assays and measurement systems
traceable to reference standards.
In terms of identifying differences between sites
and key areas of risk, the development of a stable,
well-characterized reference or surrogate cell line(s)
was emphasized by some experts as a key enabler for
process validation and identifying opportunities for
risk mitigation and management. This aligns with the
recent proposal by Viswanathan et al. (32) on the use
of these cell-based reference materials to establish
comparability among mesenchymal stromal cell
preparations, which describes the beneﬁts and re-
quirements for establishing cell-based reference ma-
terials and their global distribution. Combined with
corresponding precise and validated tests, this would
allow tolerance for critical-to-quality attributes across
multiple sites (i.e; the allowable variation) to be
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achievable variation can be reliably demonstrated to
be better than the allowable variation. This would
assist the QC and normalization of quantitative assay
data, the move from customized processes to the
development of standardized protocols, the qualiﬁca-
tion of processing equipment and implementation of
alternative continuous process validation approaches.
The sensitivity of therapeutic cells to process con-
ditions and the difﬁculty of autologous product char-
acterization enforce greater reliance on process
understanding and control to ensure product safety
and efﬁcacy. Echoed by the US regulator (27,33) but
not explicitly accepted by the EU regulator despite
indications to the contrary (28), some experts referred
to the advantages of quality designeled and contin-
uous process veriﬁcation approaches enabled by the
principles of quality by design (QbD). The QbD
approach focuses on building quality into the product
through a better assessment and mechanistic under-
standing of the effect of critical process parameters on
product critical-to-quality attributes, linking the safety
and efﬁcacy of a product, in part, to product compo-
nents and manufacturing process parameters. The
view expressed by some experts was that the applica-
tion of QbD would allow for adjustments of operating
parameters or material attributes within potentially a
larger design space, without the need to readjust
speciﬁcation acceptance criteria or to seek regulatory
approval for post-approval changes. This would allow
easier introduction of innovative new technologies into
an existing manufacturing pipeline for example, which
is currently hampered by the rigidity of manufacturing
processes that are often ﬁxed within poorly speciﬁed
and narrow process validation parameters under
traditional process validation approaches.
Experts speciﬁed the need for improved scale-down
model systems and advances in on-line, real-time
process and end-point monitoring and sensor technol-
ogy. Such technology advances would remove many
of the obstacles to the implementation of QbD
approaches, andprovidea stepchange inprocess control
capability and the potential for real-time product release
testing. By way of enabling continuous process veriﬁ-
cation, improvements in the detection, understanding
and control of variability and hence the consequences
of changes in process or product quality are expected
to substantially reduce the extent of the characteriza-
tion studies needed to show comparability between
manufacturing sites under a single product licence.Manufacturing model 3: closed or functionally closed
automated manufacture
The model asserts that MTMM autologous cellular
products manufactured by means of a closed andautomated processmay reduce the extent anddepth of
the characterization and/or validation studies needed
to show comparability between manufacturing sites
under a single product licence. The premise of the
model is that a closed or functionally closed auto-
mated device-based machine is used to manipulate
(cell expansion) and process the cells. This so-called
“GMP in-a-box” device can be validated to design
speciﬁcations by means of a cell/product-speciﬁc
protocol within a fully closed processing environment.
A single Advanced Therapy Medicinal Product
(ATMP) licence/Biologics Licence Approval (BLA)
would still be required, but only the machine would
need to be validated for a chosen indication/protocol
and not the sites in which it would be used.How do you licence a device that produces a medicinal
product?
There was consensus that engineering and produc-
tion system design solutions to the development of
highly standardized, closed or functionally closed
automated production systems may go some way to
achieving replication of the unit process of produc-
tion and achieving comparability. The view was that
such “GMP in-a-box” systems would enable simpler
scale out/roll out of MTMM autologous therapies to
multiple distributed sites by reducing the impact of
the environment in which the closed processes are
situated on the process stream. Advances in such
process technologies could provide opportunities to
exploit the potential for locating closed processes and
their supporting systems within non-classiﬁed room
environments, or so-called Controlled Not Classiﬁed
manufacturing settings. This could potentially lower
infrastructure and operational costs and the time and
cost involved in regulatory compliance for both
existing and new facilities.
From a regulatory perspective, panelists consid-
ered that a closed or functionally closed automated
production system, by removing operator variation
and the external environment, that is, the extrinsic
contamination risk from the manufacturing process,
will bring the process under control and make pro-
cess variation more predictable. Process develop-
ment and validation would be intrinsically more
straightforward, provided it was founded on Factory
Acceptance Testing of the built system and its
qualiﬁcation at each site (including the software).
However, experts emphasized that the machine
and the location or space in which it is housed must
be controlled and maintained under a Quality
Management System for every manufacturing and
QC step as scale out occurs, whether it be through
installation of additional automated systems in the
original facility, in distributed manufacturing sites in
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necessarily involve evolving GMPs that are better
suited to the setting in which the closed or func-
tionally closed manufacturing takes place, for
example, GMPs for nurses or health professionals.
Under these practices, appropriate risk-based ap-
proaches for controlling the risk of contamination
and ensuring safe operations can be used to deﬁne
the level of process and facility hygiene control and to
mitigate risks of human error or interference with
system hardware and controlling software.
Despite the hesitancy of the bioprocessing in-
dustry to enter the scaled cell manufacturing space
(34), one panelist pointed out that the development
of manufacturing technologies suitable for producing
limited clinical product designated for an individual
was evolving, for example, with devices such as the
Quantum Hollow Fibre Bioreactor (Terumo BCT)
and the Xpansion Bioreactor (ATMI). Most experts
agreed that if the advantages of closed or functionally
closed expansion systems are to be realized, advances
in the development and integration of GMP-
compliant automated solutions amenable to certain
open upstream operations (eg, cell isolation/cell pu-
riﬁcation processes) were needed. In terms of
downstream processes, if the autologous cell therapy
product is to be supplied through distributed
manufacturing sites rather than at the bedside, the
requirement for improved preservation and transport
enabling technologies to eliminate GMP-regulated
process steps for preservative removal or thawing
steps at the point of use was considered critical.
Experts referred to the regulatory challenges
involved in locating the system at the bedside,
centered on whether the system should be validated
as a piece of equipment or as a device for producing a
product licensed under ATMP or Human Cells,
Tissues and Cellular and Tissue-based Product
(HCT/P) regulations. One panelist cited the claims
and intended uses of the CliniMACs Prodigy (Mil-
tenyi Biotec) and Cellution (Cytori Therapeutics
Inc) systems as examples of where the regulatory
lines can become blurred, particularly with the cur-
rent lack of clarity and harmonization in the inter-
pretation of non-homologous use.
With such point-of-care manufacturing not
envisaged under existing US and EU regulatory
frameworks and particularly with little regulatory
heritage in this area, the challenges from a regulatory
perspective are multifactorial. For example, deter-
mining where GMP starts for a bedside device pro-
ducing an ATMP or HCT/P, how these closed or
functionally closed systems ﬁt the environment in
which they are housed and how both can be
inspected, how lot release criteria for potency and the
ﬁdelity of the products they produce is determinedand the practicality of procedures by which a quali-
ﬁed person can release ﬁnal product that is produced
for immediate administration into the patient. Ex-
perts also expressed concerns related to how avoid-
ance of compliance with quality standards can be
prevented, for example, “off label” use of products or
inappropriate re-classiﬁcation of the treatment
beyond the mandate of competent authorities. This
was highlighted as a particular concern under regu-
latory landscapes in which the deﬁnition of cell-based
products and the latitude for autologous use is less
well deﬁned than it is in Europe (14,35,36). Clari-
ﬁcation of the US and EU regulatory pathways for
the licensing of devices that produce an ATMP or
HCT/P and on the classiﬁcation of products applied
to the intended non-homologous or homologous use
of the cells at the point-of-care was recognized as
critical to the progression of product development
and regulatory compliance strategies in this area.Alternative manufacturing models
In assessing each of the proposed manufacturing
models, the following alternative models for
addressing the challenges for the scale out/roll out of
MTMM autologous cell therapy products emerged
from the panelists’ responses.Distributed manufacturing model: moving toward clinical
Centers of Excellence
Grounded on shifting the development, manufacture
and supply of autologous cell therapies away from the
donor product, biologics/drug paradigm toward the
transplant product paradigm, the premise of this
model is to move the MTMM autologous product
development and therapeutic trial process into the
hands of the medical practitioner. Regulated under
an evolutionary variant of Hospital Exemption in
Europe (17) inside dedicated clinical Centers of
Excellence for particular therapeutic areas, this
model shifts away from the “cell as a product”
concept toward an integrated service/toolebased
model of product development and manufacture. In
this model, sponsors under GMP provide the mate-
rials/components/intermediates for cell expansion
and testing, the cell expansion platforms and asso-
ciated standardized protocols to clinical Centers of
Excellence, where the cell expansion process and
therapeutic approach is optimized under the control
of the medical practitioner.
In striving to balance patient risk (and potential
beneﬁt), promote innovation and early access to
promising therapies, this model asserts that by
creating dedicated Centers of Excellence and
permitting the roll out of the standardized process
Table I. Perspectives of thought leaders on the relative strengths and weaknesses of each manufacturing model.
Strengths Weaknesses
Model 1
Inherently safer product with respect to in vitro cell stability and
potential for bio-divergence. Reduces cumulative risk factors
in the product
Even minimal expansion is judged by regulators to alter cells in a
way difﬁcult to predict without biological testing
Minimizes potential for change if controls for the permissible
number of passages and population doublings can be
established
Deﬁning the limits of safe expansion may be restricted by lack of
sensitivity and speciﬁcity of current test systems for detecting
cell transformations
Reduces cumulative risk factors in the manufacturing process by
reducing complexity and variation in the process
Donor-derived input variation will inﬂuence ex vivo expansion
potential/efﬁciency and the prospects for reproducible
manufacturing
Reduces the risks associated with pooling of samples from the
same patient, providing an opportunity to overcome product
lot volume limitations for validation and release testing in the
autologous setting
Expected that pooling would be highly scrutinized by regulators
because of concerns related to donor inter-site variability and
ethical compliance surrounding use of multiple biopsy
procedures
Limited cell processing technology barriers May have limited application for more complex products or
disease states in which high doses are required or there is an
insufﬁcient potent cell reservoir
EU and US regulatory approaches likely to be similar
Model 2
Overcomes current rigidity of poorly speciﬁed manufacturing
processes that are based on limited validation parameters.
Potentially easier introduction of innovative new technologies
into an existing manufacturing pipeline
Model is underpinned by replication of GMP systems across
multiple sites, but comparison of data to support compliance is
hampered by a lack of international standardization
Aligns with QbD-led approaches and new concepts within the
process validation guidance
Acceptance of QbD approaches differs between EU and US
regulators
Design of process validation protocols allows concurrent release
of validation lots for patient treatment at each site on the basis
of lot release test criteria and concurrent biosafety testing in
non-clinical models
Expected that regulators would view product release regimes on
the basis of end-product speciﬁcation test criteria as inadequate
for assessing impact of manufacturing changes
The integrated system of parametric release could be used to
eliminate certain speciﬁc tests of the ﬁnished product
May require availability of sufﬁciently rapid and precise surrogate
measures of potency that overcome the time and volume
constraints
Continuous validation might permit a reduction in the
characterization burden for the validation of processes at
subsequent GMP-compliant manufacturing sites
Without advances in process control capability, it is expected that
critical phases of manufacture and material control would still
require additional testing
May be appropriate for a number of speciﬁc fast-track or orphan
designation regulatory pathways under current regulatory
frame works
Sufﬁcient material volumes for validation testing and
administration to the patient may be limited
Model 3
Permits straightforward replication of the unit process of
production
Requires Factory Acceptance Testing of the built system
Removes operator-derived variation and the external
environment from the manufacturing process, making the
process more controllable, less susceptible to extrinsic
contamination, variation more predictable and validation
intrinsically simpler
Built system requires installation, operational and performance
qualiﬁcation at each site. May also require computer systems/
software compliance
Provides potential for locating manufacturing systems within
non-classiﬁed room environments or Controlled Not
Classiﬁed settings
Critical manufacturing process steps must be amenable to
automation
Lowers facility/site infrastructure costs and operational costs and
reduces time and cost involved in regulatory compliance
Poor capability and lack of integration of largely manual upstream
processes, for example, cell isolation/puriﬁcation procedures
Reduces risk of contamination and cross-contamination.
Potential for reducing the autologous donor testing
requirements in the EU
Does not eliminate need for GMP processing steps for preservative
removal and thawing if product is to be supplied through
distributed manufacturing
Under a Quality Management System and internal QC, only the
built system may need to be validated for a chosen indication/
protocol instead of the sites in which it is used
Regulatory uncertainty on whether systems for point-of-care
manufacturing should be validated as a piece of equipment or as
a device for producing a medicinal product
As a way of addressing continuous validation approaches, may
permit components of the performance qualiﬁcation to be
carried out at multiple sites
with cell line surrogates rather than product
Regulatory uncertainty related to oversight of the manufacturing
process and the clinical supply of product in point-of-care
settings
Automated closed or functionally closed cell processing
technologies are rapidly evolving
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Table II. Perspectives of thought leaders on multi-site enabler hotspots for the reproducible manufacture of MTMM autologous cellular
products.
Hotspot Thought leader perspectives
Input variation Reducing the impact of donor-derived starting material variability on the manufacturing system:
BUnderstanding and quantifying critical donor characteristics (sex, age, weight, disease state, etc) for
- Input stratiﬁcation
- Patient-speciﬁc end points
- Pharmacokinetic/pharmacodynamic models and dose regimen design
BDevelop process designs that tolerate donor-derived variability in the inputs
Upstream/downstream
processes
Reducing process and product variation:
BAdvance transformative improvements in preservation and transport enabling technologies to eliminate
GMP-regulated process steps for preservative removal or thawing
BDevelop automated functionally closed systems for cell isolation/puriﬁcation
Speciﬁcation setting Deﬁning minimal manipulation:
BEstablish the limits of safe expansion and deﬁne the edge of failure
BSet controls for permissible number of passages and population doublings; establish limits of acceptable
change
BEnable challenge studies using non- or under-functioning lots (ie, purposely degraded or over-expanded)
early in clinical development
B Improve sensitivity and speciﬁcity of cell transformation test systems
In vitro
characterization
Overcoming the time and volume constraints for pre-clinical and lot release testing in the autologous setting:
BDevelop new rapid, non-destructive, inexpensive, highly precise and sensitive characterization technologies
and test methods
“GMP in-a-box” Developing automated closed or functionally closed, regulatory-compliant manufacturing systems for cell
expansion: “GMP in-a-box”:
BUser requirement speciﬁcation applied to ATMP or HCT/P production in distributed sites, hospital settings
and at the point-of-care
BExplore opportunities for locating manufacturing systems within Controlled Not Classiﬁed settings
BDetermine GMPs that are better suited to the bedside setting
BDetermine the regulations for licensing a device that produces a medicinal product and how they can be
enacted in hospital settings
BExplore hybrid process registration strategies applicable to “GMP in-a-box” systems:
- Validate the registered process and control strategy through use of a standard set of cell lines (þVE and
eVE controls for function)
- Verify the product batch by reduced point-of-release testing on the basis of detecting out-of-speciﬁcation
behavior
Standardization Establishing methods of comparability:
BDevelop stable, well-characterized surrogate cell line(s) as a reference or “ruler” with the necessary speci-
ﬁcation and precision (“units on the ruler”)
BLink their use to automated processing systems as a way of addressing continuous validation approaches
BDevelop automated methods for their manufacture/banking and enabling systems for global distribution
Process validation Designing process validation studies sufﬁcient for regulatory approval of additional manufacturing sites:
BLink the use of surrogate cell lines to “GMP in-a-box” systems as a way of addressing continuous
validation approaches
BDevelop process control capabilities to permit continuous process veriﬁcation approaches and expand the
use of concurrent product release approaches
Regulatory framework Clarifying regulatory pathways:
BDevelop better tools to support an objective assessment framework that:
- Balances patient beneﬁt with levels of risk
- Balances regulation at translational bottlenecks (eg, comparability)
- Promotes innovation
- Accelerates clinical experience and early access to promising autologous therapies
BDebate the role of regulator and other stakeholders in the risk/beneﬁt decisions, speciﬁcally “GMP in-a-box”
and point-of-care manufacturing
BCapture learning from real product experiences to develop better tools for a risk/beneﬁt framework
BExplore opportunities for investigator-led initiatives for patient-designated clinical production within clinical
Centers of Excellence under the scope of the practice of medicine
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apeutic network can be built to coordinate best
practices and accelerate clinical experience in the cell
therapy space. In principle, through an open devel-
opment mechanism intended to make clinical trial
design and data transparent, the model wouldstimulate both intellectual and ﬁnancial investment
in later-stage cell therapies This would open oppor-
tunities for co-development of therapies/test regimes
with industry and for facilitating the pull and adop-
tion of new treatments as the standard of care in
clinical practice.
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ensure a chain of command and associated reporting
requirements for data collection, for example, who
veriﬁes QC/QA and lot release of the ﬁnal product?
Who determines what is safe and what is not, in terms
of dose and delivery of the cell therapy? Can you
ensure control of the product production process and
prevent “off-label” use? Who funds the development
and operational costs of the process and how are the
operator and the therapeutic sponsor reimbursed?
Can the model be expanded and applied to banking
material for acute indications?Hybrid manufacturing model: maturing the concepts of
models 1e3 for distributed manufacturing
The premise of this hybrid model is a move toward a
more controlled manufacturing process, building and
integrating the concepts of model 1 and model 2. The
hybrid model would realize the lower risks associated
with limited expansion and overcome time- and vol-
ume-limiting constraints while maintaining sterility
and managing risk through the development of a
closed or functionally closed automated device
(“GMP in-a-box”) that manufactures an MTMM
autologous therapy at the factory or at the point-of-
care. This model asserts that by minimizing the
impact of manufacturing site and operator variability
andmaximizing the reduction of risk, the extent of the
characterization/validation studies needed to show
comparability between manufacturing sites under a
single product licence may be reduced.Summary
This paper addresses one of the key current chal-
lenges in cell therapy manufacturing. It has used the
literature and views of a panel of key thought leaders
in the industrial and regulatory community to deﬁne
critical areas that must be addressed to allow clini-
cally led MTMM autologous therapies to be rolled
out in the event of their success at a single site. We
have proposed three prospective manufacturing
models, considered how they might be enabled and
tested their prospects for addressing the challenge
of product comparability under the principles of
the existing regulatory landscape. Alternative
manufacturing models emerging from the panelists’
responses were also captured to solicit further
assessment and comment.
The existing regulations remain uncompro-
mising with respect to the level of assurance
required to demonstrate comparability after the roll
out of processes to multiple manufacturing sites
post-clinical trial, either within the same (Nþ1
model) or different jurisdictions (NþMmodel). It isnot yet clear which of these manufacturing and
distribution approaches will be most suitable under
the existing regulatory frameworks. Each
manufacturing model has its strengths and weak-
nesses, reﬂecting the varying perspectives of panel
(Table I).
Although many of the manufacturing and
operational constraints identiﬁed in this paper are
well understood and common to all cell therapy
manufacture, the perspectives and insights of the
panel have identiﬁed speciﬁc and additional chal-
lenges for the manufacture of MTMM autologous
cell therapies. Driven by the need to scale out
manufacture while containing cost of goods and
costs of validation and by the potential need to
manufacture therapies at the point-of-care or in
hospital settings, Table II summarizes the per-
spectives of the thought leaders on where opera-
tional, technological and scientiﬁc improvements
should be prioritized and where new enabling sci-
ence is still required. Extending across all of the
manufacturing models, the following discussion
expands on the requirements and opportunities
identiﬁed in Table II.
With each product lot representing a unique
donor, differences between tissue sources and indi-
vidual donor characteristics, compounded by the
poor capability of upstream isolation methods, create
greater potential for product variability in the autol-
ogous setting. Better quality control of the source
and nature of the donor-derived starting material is
needed so that minimum thresholds for justifying the
process input can be established and patient-speciﬁc
end points relative to the characteristics of the patient
can be derived.
To maximize the favorable safety and risk proﬁle
provided by short-term autologous cell culture, a
scientiﬁc basis for the limits of safe expansion must
be established. This would allow controls to be set
for the permissible number of passages and popula-
tion doublings to minimize the potential for change.
Scale out efﬁciencies for individualized production
would be facilitated by the transition to automated
closed or functionally closed and regulatory-
compliant manufacturing technologies (“GMP in-a-
box” systems), suitable for producing limited clinical
ATMPs or HCT/Ps designated for an individual.
With the wide variety of potential tissue sour-
ces, advances in the development of integrated,
GMP-compliant, closed automated platforms
amenable to upstream cell isolation/puriﬁcation
procedures are required to reduce intra-donor and
inter-donorederived variability in expansion pro-
cess efﬁciency. They may also provide the potential
for within-patient cell pooling, if ethically
justiﬁable.
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enabling technologies to eliminate GMP-regulated
process steps for preservative removal or thawing will
be transformative for the development and supply of
autologous cell therapy products through distributed
manufacturing sites.
Clariﬁcation of the US and EU regulatory path-
ways, both for the licensing of devices that produce
an ATMP or HCT/P and for the classiﬁcation of
products applied to the intended non-homologous or
homologous use of the cells at the point-of-care, is
required if alternative business models are to be
progressed in this area.
Despite the emerging safety proﬁle of autologous
therapies, arguably clinical applications for MTMM
autologous therapies will continue to be in patients
with unmet medical conditions and ultra-rare or life-
threatening diseases under “special” regulatory path-
ways. If regulatory bodies are to enhance proactivity in
their stated aim to protect, promote and improve
public health, better tools are required to support an
objective assessment framework that balances patient
beneﬁt with corresponding levels of risk, promotes
innovation, expedites the demonstration of compara-
bility and accelerates clinical experience and early
access to promising autologous therapies.
Further debate on the role of regulators and
stakeholders in the risk/beneﬁt decisions and on the
process for formation of the regulation is called for,
speciﬁcally for concepts such as “GMP in-a-box”
and point-of-care manufacturing. Developers will
need to openly engage with the regulator to inform
this framework by capturing the learning from real
product experiences.
The emergence of new regulatory paradigms such
as those recently adopted in South Korea, Japan and
Australia, for example, could affect national
competitive advantage. The intense debate between
regulators, law makers and practitioners (37e41)
underscores the need for clariﬁcation within existing
US and EU regulatory frameworks on the role and
opportunities for investigator-based initiatives for
patient-designated clinical production within clinical
Centers of Excellence under the scope of the practice
of medicine.
As proposed by Rao (personal communication,
2013), the development of stable, well-characterized
surrogate cell line(s) is fundamental to establishing
methods of comparability. Linking their use to
automated processing systems as way of addressing
continuous validation approaches, these surrogates,
acting as a reference or “ruler” with the necessary
speciﬁcation and precision (“units on the ruler”),
could provide an inexpensive and simple way to
compare manufacturing processes at multiple sites or
between processing equipment.Acknowledgments
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